Rhenman & Partners Asset Management AB Purchases 240,000 Shares of Kura Oncology, Inc. $KURA

Rhenman & Partners Asset Management AB increased its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 96.0% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 490,000 shares of the company’s stock after buying an additional 240,000 shares during the period. Rhenman & Partners Asset Management AB owned 0.56% of Kura Oncology worth $4,336,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Kura Oncology by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio bought a new position in shares of Kura Oncology in the first quarter worth approximately $143,000. Teacher Retirement System of Texas raised its stake in Kura Oncology by 29.3% in the second quarter. Teacher Retirement System of Texas now owns 16,235 shares of the company’s stock valued at $94,000 after purchasing an additional 3,683 shares in the last quarter. Savant Capital LLC lifted its position in Kura Oncology by 74.1% during the second quarter. Savant Capital LLC now owns 87,974 shares of the company’s stock valued at $508,000 after purchasing an additional 37,450 shares during the last quarter. Finally, Fox Run Management L.L.C. lifted its position in Kura Oncology by 31.5% during the second quarter. Fox Run Management L.L.C. now owns 31,546 shares of the company’s stock valued at $182,000 after purchasing an additional 7,557 shares during the last quarter.

Insider Buying and Selling at Kura Oncology

In other news, SVP Thomas James Doyle sold 7,142 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $60,421.32. Following the transaction, the senior vice president directly owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. The trade was a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 8,180 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider directly owned 267,274 shares of the company’s stock, valued at $2,261,138.04. The trade was a 2.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 59,794 shares of company stock worth $537,176 over the last three months. 6.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on KURA. Wall Street Zen lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Thursday, February 26th. Finally, Leerink Partners set a $20.00 price objective on shares of Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.71.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near‑term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET‑017 frontline trials, KOMET‑007 combos, FIT‑001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $8.96 on Friday. The company’s fifty day simple moving average is $8.75 and its two-hundred day simple moving average is $9.41. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $12.49. The firm has a market cap of $779.70 million, a PE ratio of -2.82 and a beta of 0.22. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). The firm had revenue of $17.34 million for the quarter, compared to analysts’ expectations of $34.71 million. Kura Oncology had a negative return on equity of 91.62% and a negative net margin of 412.95%. As a group, equities analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.